【Summary Description】 On June 16, 2023, Seefunge Pharmaceutical Technology Co., Ltd. and OVCTEK Co. Ltd. entered into a joint venture agreement in Hefei, Anhui Province, China.

On June 16, 2023, Seefunge Pharmaceutical Technology Co., Ltd. and OVCTEK Co. Ltd. entered into a joint venture agreement in Hefei, Anhui Province, China.

Relying on the resources and advantages of both parties in the field of ophthalmic drugs, the joint venture company intends to engage in the research and development, production and sales of 0.01% and 0.02% atropine sulfate eye drops, etc. After the establishment of the joint venture company, it is planned to start the preparatory work for the phase III clinical trial of low-concentration atropine soon.

Seefunge Pharmaceutical Technology Co., Ltd. and OVCTEK Co. Ltd. intend to jointly invest in the establishment of Anhui Oupushifang Pharmaceutical Technology Co., Ltd. The registered capital of the joint venture company is 28 million yuan, of which OVCTEK Investment Co. Ltd. invests 18.2 million yuan, accounting for 65% of the total registered capital, and Seefunge invests 9.8 million yuan, accounting for 35% of the total registered capital.

 

About Seefunge

Seefunge Pharmaceutical Technology Co., Ltd. is a technology-based enterprise specializing in the transformation of ophthalmic research and industry incubation. The company focuses on the management of the entire lifecycle of the ophthalmic industry.

The company is headquartered in Hangzhou, Zhejiang Province, China. The company is committed to continuous preclinical research and clinical development through the discovery and linkage of ophthalmic innovation resources from global research institutes and organizations, and has more than 20 innovative drugs and specialty generic drug projects under development, which have already covered a wide range of therapeutic areas such as myopia, glaucoma, dry eye and fundus diseases.

About OVCTEK

OVCTEK Co. Ltd. is a high-tech enterprise specializing in eye health and myopia prevention and control technology and services, with more than 300 subsidiaries and nearly 3,000 employees (including subsidiaries).

The business of OVCTEK includes two major segments: ophthalmic and optometric medical devices (products) and medical services. In terms of products, the current main products are keratoplasty lenses and other rigid contact lenses (contact lenses) as well as ancillary care products, and it is the world's leading R&D and production enterprise of keratoplasty lenses.

In terms of medical and optometric services, the company holds and participates in 23 eye hospitals. Meanwhile, it has nearly 400 eye clinics, outpatient clinics and optometry centers nationwide. The company is increasing and accelerating its investment layout in the medical service field, and intends to form a nationwide eye health and myopia prevention and control service network.